Oppenheimer & CO Inc Bluebird Bio, Inc. Transaction History

Oppenheimer & CO Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$11.24 - $21.0 $130,788 - $244,356	-11,636 Closed	0 $0
Q2 2021 Aug 03, 2021	BUY	$18.04 - $22.09 $209,913 - $257,039	11,636 New	11,636 $372,000
Q1 2021 May 10, 2021	SELL	$16.59 - $33.89 $80,162 - $163,756	-4,832 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$27.5 - $37.92 $27,170 - $37,464	988 Added 25.7%	4,832 $209,000
Q3 2020 Nov 13, 2020	BUY	$34.44 - $43.75 $19,424 - $24,675	564 Added 17.2%	3,844 $208,000

Q2 2020 Aug 11, 2020	BUY	$27.12 - $45.97 $88,953 - $150,781	3,280 New	3,280 $200,000
Q3 2019 Oct 31, 2019	SELL	$59.47 - $93.1 $105,856 - $165,718	-1,780 Closed	0 $0
Q1 2019 Apr 24, 2019	BUY	$64.44 - $104.11 $114,703 - $185,315	1,780 New	1,780 $280,000

173

104M

827K

1.23M

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $75.6M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.